Theravid

Theravid is a biotechnology company focused on developing next-generation theranostic agents for the precision diagnosis and treatment of cancer. The company leverages a proprietary platform to design small molecule ligands that target specific biomarkers, such as Prostate-specific membrane antigen (PSMA), with high affinity and selectivity. By pairing these ligands with different radioisotopes, Theravid aims to provide a seamless transition from molecular imaging to targeted radiotherapy. Their lead programs are currently in the pre-clinical stage, targeting advanced prostate cancer with the goal of improving patient outcomes through personalized medicine.